DE69637486D1 - 'Osteoclast-Inhibitor Faktor' (OCIF) abgeleitete Proteinen und Methoden zu dessen Gewinnung - Google Patents

'Osteoclast-Inhibitor Faktor' (OCIF) abgeleitete Proteinen und Methoden zu dessen Gewinnung

Info

Publication number
DE69637486D1
DE69637486D1 DE69637486T DE69637486T DE69637486D1 DE 69637486 D1 DE69637486 D1 DE 69637486D1 DE 69637486 T DE69637486 T DE 69637486T DE 69637486 T DE69637486 T DE 69637486T DE 69637486 D1 DE69637486 D1 DE 69637486D1
Authority
DE
Germany
Prior art keywords
protein
production
ocif
methods
derived proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637486T
Other languages
English (en)
Inventor
Masaaki Goto
Eisuke Tsuda
Shin Ichi Mochizuki
Kazuki Yano
Fumie Kobayashi
Nobuyuki Shima
Hisataka Yasuda
Nobuaki Nakagawa
Tomonori Morinaga
Masatsugu Ueda
Kanji Higashio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of DE69637486D1 publication Critical patent/DE69637486D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69637486T 1995-02-20 1996-02-20 'Osteoclast-Inhibitor Faktor' (OCIF) abgeleitete Proteinen und Methoden zu dessen Gewinnung Expired - Lifetime DE69637486D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5497795 1995-02-20
JP20750895 1995-07-21

Publications (1)

Publication Number Publication Date
DE69637486D1 true DE69637486D1 (de) 2008-05-15

Family

ID=26395808

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637486T Expired - Lifetime DE69637486D1 (de) 1995-02-20 1996-02-20 'Osteoclast-Inhibitor Faktor' (OCIF) abgeleitete Proteinen und Methoden zu dessen Gewinnung
DE69633225T Expired - Lifetime DE69633225T2 (de) 1995-02-20 1996-02-20 OCIF-Protein und Verfahren zu dessen Gewinnung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69633225T Expired - Lifetime DE69633225T2 (de) 1995-02-20 1996-02-20 OCIF-Protein und Verfahren zu dessen Gewinnung

Country Status (20)

Country Link
US (9) US7125686B1 (de)
EP (2) EP0816380B1 (de)
JP (1) JP3502102B2 (de)
KR (1) KR100381788B1 (de)
CN (1) CN1218961C (de)
AT (2) ATE391178T1 (de)
AU (1) AU702557C (de)
CA (1) CA2213469A1 (de)
DE (2) DE69637486D1 (de)
ES (1) ES2227579T3 (de)
FI (1) FI973402A (de)
HU (1) HU224570B1 (de)
IL (1) IL117175A (de)
MX (1) MX9706341A (de)
NO (1) NO318898B1 (de)
NZ (1) NZ301362A (de)
PT (1) PT816380E (de)
RU (2) RU2194714C2 (de)
TW (1) TW538049B (de)
WO (1) WO1996026217A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
AU2159995A (en) * 1995-03-15 1996-10-02 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
JPH1057071A (ja) * 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP0961832A4 (de) * 1996-09-18 2003-02-26 Human Genome Sciences Inc Menschliche tumornekrosefaktorrezeptor-ähnliche gene
DE69738811D1 (de) * 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
HU229841B1 (en) 1997-04-15 2014-09-29 Daiichi Sankyo Co Ltd Antibodies against obm
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
EP1009856A4 (de) * 1997-04-18 2003-02-12 Millennium Pharm Inc Moleküle einer mit fthma-070 verwandten proteinfamilie und die mit t85 verwandte proteinfamilie und ihre verwendung
JP2002514079A (ja) * 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
KR100547395B1 (ko) * 1997-09-24 2006-02-01 산쿄 가부시키가이샤 골대사이상증의 진단방법
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
US6087555A (en) * 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
JPH11155420A (ja) * 1997-12-02 1999-06-15 Snow Brand Milk Prod Co Ltd トランスジェニック動物
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
WO2000021554A1 (fr) * 1998-10-09 2000-04-20 Sankyo Company, Limited Prevention et traitement de la cachexie
TR200101146T2 (tr) * 1998-10-28 2001-09-21 Sankyo Co., Ltd. Kemik-patobolizmasını tedavi edici madde.
AUPQ167599A0 (en) * 1999-07-19 1999-08-12 St. Vincent's Institute Of Medical Research Inhibitor of osteoclast precursor formation
WO2001023562A2 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoprotegerin regulatory region
JP2001103964A (ja) * 1999-10-05 2001-04-17 Teijin Ltd 破骨細胞形成抑制方法または骨吸収抑制方法
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
AU2002231602A1 (en) * 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
CN1238379C (zh) * 2001-03-21 2006-01-25 中国科学院上海生命科学研究院 新的破骨细胞形成抑制因子、其编码序列及用途
BR0208554A (pt) * 2001-04-03 2004-03-02 Nestle Sa Osteoprotegerina no leite
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
EP1270015A3 (de) * 2001-06-29 2004-02-25 Sankyo Company Limited Ein Komplex enthaltend OCIF und einem Polysaccharid
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1482978A1 (de) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmazeutische zusammensetzung enthaltend osteoklastogenesishemmungsfaktor
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
JP2006509504A (ja) * 2002-12-11 2006-03-23 ユニバーシティー オブ マサチューセッツ 脂肪細胞へのｓｉＲＮＡの導入方法
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA2602022C (en) * 2005-04-19 2016-03-22 Gabriel Stavros Panayi Binding immunoglobulin protein (bip) for prevention or treatment of bone conditions or diseases
EP1948245B1 (de) * 2005-10-24 2011-10-05 University of Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
JP5261187B2 (ja) * 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
US10741034B2 (en) 2006-05-19 2020-08-11 Apdn (B.V.I.) Inc. Security system and method of marking an inventory item and/or person in the vicinity
ES2540733T3 (es) * 2007-10-11 2015-07-13 Daiichi Sankyo Company, Limited Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
CA2704056A1 (en) * 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
BRPI1006134A2 (pt) 2009-04-09 2016-02-23 Daiichi Sankyo Co Ltd anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
TW201219568A (en) 2010-10-05 2012-05-16 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-related protein Siglec-15
CN102011025A (zh) * 2010-10-11 2011-04-13 宁波市鄞州品达电器焊料有限公司 一种耐超高温的无铅焊锡
US9464133B2 (en) 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
US9963740B2 (en) * 2013-03-07 2018-05-08 APDN (B.V.I.), Inc. Method and device for marking articles
EP3058339B1 (de) 2013-10-07 2019-05-22 APDN (B.V.I.) Inc. Multimodales bild und spektraler leser
WO2015142990A1 (en) 2014-03-18 2015-09-24 Apdn (B.V.I.) Inc. Encryped optical markers for security applications
US10745825B2 (en) 2014-03-18 2020-08-18 Apdn (B.V.I.) Inc. Encrypted optical markers for security applications
JP6339855B2 (ja) * 2014-05-14 2018-06-06 住友ゴム工業株式会社 エアレスタイヤ及びその製造方法
EP3442719B1 (de) 2016-04-11 2021-09-01 APDN (B.V.I.) Inc. Verfahren zur markierung von cellulosischen produkten
US10995371B2 (en) 2016-10-13 2021-05-04 Apdn (B.V.I.) Inc. Composition and method of DNA marking elastomeric material
WO2018156352A1 (en) 2017-02-21 2018-08-30 Apdn (B.V.I) Inc. Nucleic acid coated submicron particles for authentication

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127637A (en) * 1872-06-04 Improvement in couplings for divided axles
US86826A (en) * 1869-02-09 Improvement in mechanical movement
US86827A (en) * 1869-02-09 Improved rubber boot
US81720A (en) * 1868-09-01 Isaac williams
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US175840A (en) * 1876-04-11 Improvement in circular-knitting machines
US104485A (en) * 1870-06-21 Improvement in sleeping-cars
US176647A (en) * 1876-04-25 Improvement in car-couplings
US166097A (en) * 1875-07-27 Improvement in buttons for wearing apparel
US169117A (en) * 1875-10-26 Improvement in revolution-indicators
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US100488A (en) * 1870-03-01 Improved tire-xjfsetting machine
US150989A (en) * 1874-05-19 Improvement in pin and dowel machines
US207827A (en) * 1878-09-10 Improvement in siphon-condensers
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US208045A (en) * 1878-09-17 Improvement in ether-meters for refrigerating-machines
US33535A (en) * 1861-10-22 Improvement in machines for making bricks
US144480A (en) * 1873-11-11 Improvement in cutting attachments for sewing-machines
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US103978A (en) * 1870-06-07 Improvement in bee-hives
US100069A (en) * 1870-02-22 Geokge h
US886826A (en) * 1907-12-14 1908-05-05 Reece Button Hole Machine Co Button-sewing machine.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0192658A4 (de) 1984-07-30 1987-07-13 Salk Inst For Biological Studi Retrovirale gentransfervektoren.
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JP2604135B2 (ja) 1986-02-28 1997-04-30 ライオン株式会社 口腔骨疾患治療剤
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
WO1990004417A1 (en) * 1988-10-24 1990-05-03 Bruce Caterson Methods of and compositions for diagnosing, monitoring and treating the early stages of osteoarthritis
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
TW318142B (de) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5366859A (en) * 1991-10-31 1994-11-22 Mitsubishi Petrochemical Co., Ltd. Radioimmunoassay method
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
AU672606B2 (en) 1992-04-30 1996-10-10 Amgen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0725800B1 (de) 1993-09-14 2001-06-27 Merck & Co. Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
NZ288352A (en) * 1994-06-27 1997-12-19 Snow Brand Milk Products Co Ltd Protein with osteoblast proliferating activity recombinant production
EP0727211A1 (de) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Verwendung von src SH2-spezifische Verbindungen zur Behandlung von Knochenresorptionserkrankungen
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) * 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
DE69738811D1 (de) 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
HU229841B1 (en) 1997-04-15 2014-09-29 Daiichi Sankyo Co Ltd Antibodies against obm
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
KR100547395B1 (ko) 1997-09-24 2006-02-01 산쿄 가부시키가이샤 골대사이상증의 진단방법
US6297022B1 (en) * 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
TR200101146T2 (tr) 1998-10-28 2001-09-21 Sankyo Co., Ltd. Kemik-patobolizmasını tedavi edici madde.
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
EP1270015A3 (de) 2001-06-29 2004-02-25 Sankyo Company Limited Ein Komplex enthaltend OCIF und einem Polysaccharid
EP1482978A1 (de) 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmazeutische zusammensetzung enthaltend osteoklastogenesishemmungsfaktor
WO2008016380A2 (en) 2005-12-23 2008-02-07 J. Craig Venter Institute Installation of genomes or partial genomes into cells or cell-like systems

Also Published As

Publication number Publication date
IL117175A (en) 2005-11-20
US20050014229A1 (en) 2005-01-20
EP1528103A1 (de) 2005-05-04
JP3502102B2 (ja) 2004-03-02
RU2002120050A (ru) 2004-03-27
CN1218961C (zh) 2005-09-14
DE69633225T2 (de) 2005-09-01
EP1528103B1 (de) 2008-04-02
KR19980702369A (ko) 1998-07-15
AU702557C (en) 2004-11-04
RU2194714C2 (ru) 2002-12-20
WO1996026217A1 (fr) 1996-08-29
CA2213469A1 (en) 1996-08-29
NO318898B1 (no) 2005-05-18
ES2227579T3 (es) 2005-04-01
US20050124054A1 (en) 2005-06-09
EP0816380A1 (de) 1998-01-07
FI973402A (fi) 1997-10-17
ATE391178T1 (de) 2008-04-15
FI973402A0 (fi) 1997-08-20
US6855808B2 (en) 2005-02-15
US7205397B2 (en) 2007-04-17
EP0816380A4 (de) 1998-11-18
NZ301362A (en) 1999-11-29
ATE274580T1 (de) 2004-09-15
EP0816380B1 (de) 2004-08-25
NO973801L (no) 1997-10-20
DE69633225D1 (de) 2004-09-30
AU4677396A (en) 1996-09-11
US20030153048A1 (en) 2003-08-14
RU2238948C2 (ru) 2004-10-27
MX9706341A (es) 1998-08-30
HUP9900422A1 (hu) 1999-06-28
KR100381788B1 (ko) 2003-08-02
US20050026837A1 (en) 2005-02-03
US20040143859A1 (en) 2004-07-22
US20020051969A1 (en) 2002-05-02
HU224570B1 (hu) 2005-10-28
US20050118682A1 (en) 2005-06-02
US20040142426A1 (en) 2004-07-22
CN1175956A (zh) 1998-03-11
TW538049B (en) 2003-06-21
US7468268B2 (en) 2008-12-23
AU702557B2 (en) 1999-02-25
IL117175A0 (en) 1996-06-18
HUP9900422A3 (en) 2002-11-28
PT816380E (pt) 2004-12-31
NO973801D0 (no) 1997-08-19
US7125686B1 (en) 2006-10-24
US7276344B2 (en) 2007-10-02

Similar Documents

Publication Publication Date Title
DE69637486D1 (de) 'Osteoclast-Inhibitor Faktor' (OCIF) abgeleitete Proteinen und Methoden zu dessen Gewinnung
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
DE69029657D1 (de) Menschliches cytokin, interleukin-9
ATE277078T1 (de) N-terminal modifizierte polypeptide, und herstellungsprozess
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
DE69333346T2 (de) Neuartiges p- selectin ligandenprotein
DE3788229T3 (de) Verfahren zur isolierung von ca 125-antigen.
DE69319012T2 (de) Protein mit Knochenbildungs-Eigenschaften und Verfahren zu seiner Herstellung
DE69332471T2 (de) Verfahren zur herstellung modifizierten proteine
ATE239494T1 (de) Heparin-binding protein zur behandlung von sepsis
Jaffe et al. Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line
EP1070758A4 (de) Neues protein und verfahren zu dessen herstellung
Wagner NIF (neurite-inducing factor): a novel peptide inducing neurite formation in PC12 cells
JPH0725798B2 (ja) ＴＧＦ−β制御糖タンパク質
MX9600765A (es) Proteina y metodos para producir la proteina.
ATE301672T1 (de) Methode zur reinigung eines erythrpoietinbindenden proteins
AU4315396A (en) Monoclonal antibody
FAUVEL et al. Application of HPLC to the Separation of Glycoproteins from Endothelial Cell Culture Medium
ATE299893T1 (de) Verfahren zur herstellung von humanen (alpha) leukozyteninterferon
KR880701735A (ko) 골 유도 조성물
DE69126379D1 (de) Verfahren zur herstellung und reinigung des carboxyterminalen fragments der dna-polymerase i von streptococcus pneumoniae

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation